These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 548256)

  • 41. Economic benefits of using adaptive predictive models of reproductive toxicity in the context of a tiered testing program.
    Martin MT; Knudsen TB; Judson RS; Kavlock RJ; Dix DJ
    Syst Biol Reprod Med; 2012 Feb; 58(1):3-9. PubMed ID: 22239076
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment.
    Adeleye Y; Andersen M; Clewell R; Davies M; Dent M; Edwards S; Fowler P; Malcomber S; Nicol B; Scott A; Scott S; Sun B; Westmoreland C; White A; Zhang Q; Carmichael PL
    Toxicology; 2015 Jun; 332():102-11. PubMed ID: 24582757
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New approaches to immunotoxicity testing.
    Archer DL
    Environ Health Perspect; 1982 Feb; 43():109-13. PubMed ID: 7037382
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Application of immunocompetence assays for defining immunosuppression.
    Dean JH; Padarathsingh ML; Jerrells TR
    Ann N Y Acad Sci; 1979 May; 320():579-90. PubMed ID: 110201
    [No Abstract]   [Full Text] [Related]  

  • 45. [Experimental study of the effect of Anthio and Milbex on immunobiological reactivity and on certain autoimmune processes in the body].
    Aripdzhanov TM
    Gig Sanit; 1973 May; 38(5):101-2. PubMed ID: 4769782
    [No Abstract]   [Full Text] [Related]  

  • 46. An in vivo model for assessing effects of drugs and toxicants on immunocompetence.
    Speirs RS; Speirs EE
    Drug Chem Toxicol; 1979; 2(1-2):19-33. PubMed ID: 548253
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing.
    Thybaud V; Aardema M; Clements J; Dearfield K; Galloway S; Hayashi M; Jacobson-Kram D; Kirkland D; MacGregor JT; Marzin D; Ohyama W; Schuler M; Suzuki H; Zeiger E;
    Mutat Res; 2007 Feb; 627(1):41-58. PubMed ID: 17126066
    [TBL] [Abstract][Full Text] [Related]  

  • 48. FIFRA Subdivision F testing Guidelines: are these tests adequate to detect potential hormonal activity for crop protection chemicals? Federal Insecticide, Fungicide, and Rodenticide Act.
    Stevens JT; Tobia A; Lamb JC; Tellone C; O'Neal F
    J Toxicol Environ Health; 1997 Apr; 50(5):415-31. PubMed ID: 9140462
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A predictive data-driven framework for endocrine prioritization: a triazole fungicide case study.
    Paul Friedman K; Papineni S; Marty MS; Yi KD; Goetz AK; Rasoulpour RJ; Kwiatkowski P; Wolf DC; Blacker AM; Peffer RC
    Crit Rev Toxicol; 2016 Oct; 46(9):785-833. PubMed ID: 27347635
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current and future needs for developmental toxicity testing.
    Makris SL; Kim JH; Ellis A; Faber W; Harrouk W; Lewis JM; Paule MG; Seed J; Tassinari M; Tyl R
    Birth Defects Res B Dev Reprod Toxicol; 2011 Oct; 92(5):384-94. PubMed ID: 21922641
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The pharmacological and immunological basis for the use of immunosuppressive drugs.
    Bach JF
    Drugs; 1976; 11(1):1-13. PubMed ID: 770130
    [No Abstract]   [Full Text] [Related]  

  • 52. Key learnings from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 in vitro assays.
    LeBaron MJ; Coady KK; O'Connor JC; Nabb DL; Markell LK; Snajdr S; Sue Marty M
    Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):23-42. PubMed ID: 24515815
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [A system for assessment of chemical substances on mutagenicity in man: general priniciples, practical recommendations and further elaboration].
    Bochkov NP; Shram RI; Kuleshov NP; Zhurkov VS
    Genetika; 1975; 11(10):156-69. PubMed ID: 1225748
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chemical-induced immunomodulation.
    Koller LD
    J Am Vet Med Assoc; 1982 Nov; 181(10):1102-6. PubMed ID: 6816774
    [No Abstract]   [Full Text] [Related]  

  • 55. Lactoferrin accelerates reconstitution of the humoral and cellular immune response during chemotherapy-induced immunosuppression and bone marrow transplant in mice.
    Artym J; Zimecki M; Kuryszko J; Kruzel ML
    Stem Cells Dev; 2005 Oct; 14(5):548-55. PubMed ID: 16305339
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Effect of the anticoagulant nafarin on the immunological reactivity].
    Kovalev IE; Lakin KM
    Farmakol Toksikol; 1967; 30(6):696-9. PubMed ID: 5598440
    [No Abstract]   [Full Text] [Related]  

  • 57. Immunotoxicology: An overview.
    Dean JH
    Toxicol In Vitro; 1994 Oct; 8(5):933-7. PubMed ID: 20693049
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Single-organism model of host defense against infection: a novel immunotoxicologic approach to evaluate immunomodulatory drugs.
    Herzyk DJ; Ruggieri EV; Cunningham L; Polsky R; Herold C; Klinkner AM; Badger A; Kerns WD; Bugelski PJ
    Toxicol Pathol; 1997; 25(4):351-62. PubMed ID: 9280118
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunotoxicant screening and prioritization in the twenty-first century.
    Luebke R
    Toxicol Pathol; 2012; 40(2):294-9. PubMed ID: 22105646
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vivo assessment of immunotoxicity.
    Munson AE; Sanders VM; Douglas KA; Sain LE; Kauffmann BM; White KL
    Environ Health Perspect; 1982 Feb; 43():41-52. PubMed ID: 7060547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.